Table 2.
A comparison of the change in surrogate markers for the risk of progression to type-2 diabetes over time in patients with pre-diabetes assigned either to usual management or a 6-month diet and lifestyle-change package (analysis of covarience).
| Change from baseline | |||
|---|---|---|---|
| Control group (n = 11)a, mean (SD) | Intervention group, n = 17, mean (SD) | Adjusted differenceb (95% CI), P-value | |
| Weight, kg | −0.30 (1.36) | −2.73 (3.15) | 2.4 (0.3 to 4.6), 0.03 |
| BMI, kg/m2 | −0.10 (0.47) | −0.91 (1.01) | 0.8 (0.1 to 1.5), 0.03 |
| Abdominal circumference, cm | −1.18 (2.27) | −6.01 (3.80) | 5.2 (2.6 to 7.8), <0.01 |
| Fasting glucose, mmol/l | 0.25 (0.67) | −0.02 (0.46) | 0.4 (0.0 to 0.7), 0.049 |
| Total cholesterol, mmol/l | −0.13 (0.55) | −0.33 (0.74) | 0.2 (−0.4 to 0.7), 0.53 |
| Total cholesterol/high-density lipoprotein ratioc | −0.50 (1.09) | −0.27 (0.66) | −0.4 (−1.5 to 0.9), 0.56 |
| Triglycerides, mmol/l | −0.14 (0.55) | −0.24 (0.75) | 0.05 (−0.3 to 0.4), 0.79 |
a
Average length of control phase 21.1 weeks (range 14-31 weeks).
b
Diference in the outcomes at 6 months between the two groups, adjusted for baseline.
c
Controls n = 4, intervention n = 9.